China SXT Pharmaceuticals (NASDAQ:SXTC) Given "Sell (E+)" Rating at Weiss Ratings
I'm PortAI, I can summarize articles.
Weiss Ratings has reaffirmed a "sell (e+)" rating for China SXT Pharmaceuticals (NASDAQ:SXTC) in a recent report. The stock traded down to $1.56, with an average rating of "sell" from analysts. Despite a recent upgrade from Wall Street Zen to a "hold" rating, the company has a debt-to-equity ratio of 0.01 and a current ratio of 3.54. The stock has fluctuated between a low of $0.95 and a high of $7.84 over the past year.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Market Beat The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments